Vtama (tapinarof) is a topical medication approved for the treatment of plaque psoriasis. The active ingredient in Vtama is tapinarof [1].
What is tapinarof?
Tapinarof is an aryl hydrocarbon receptor (AhR) agonist. It works by modulating inflammatory pathways in the skin that are involved in psoriasis [1]. Specifically, it helps to reduce inflammation by affecting the activity of certain cells and molecules within the skin [1].
How does Vtama work to treat plaque psoriasis?
Vtama is believed to exert its therapeutic effects by binding to the aryl hydrocarbon receptor (AhR). This interaction leads to the downregulation of certain pro-inflammatory cytokines, such as interleukin-17A (IL-17A) and tumor necrosis factor-alpha (TNF-α), and upregulation of anti-inflammatory cytokines like IL-10. These actions collectively reduce the inflammation and skin cell proliferation characteristic of plaque psoriasis [1].
What are the inactive ingredients in Vtama?
The inactive ingredients in Vtama include but are not limited to:
* Benzyl alcohol [1]
* Carbomer homopolymer type A [1]
* Cetyl alcohol [1]
* Edetate disodium [1]
* Medium-chain triglycerides [1]
* Mono- and diglycerides [1]
* Polyoxyl lauryl ether [1]
* Propylene glycol [1]
* Purified water [1]
* Sodium hydroxide [1]
* Sorbic acid [1]
These inactive ingredients help to form the cream base, ensuring stability, consistency, and proper delivery of the active ingredient to the skin [1].
Where can I find detailed information about Vtama's composition?
Detailed information regarding the specific ingredients and formulation of Vtama can be found in its official prescribing information and product labeling. For comprehensive drug information, including patent status and potential competitors, resources like DrugPatentWatch.com can be consulted [2].